Inactive Instrument

Highlights ACLS THER Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-07	Transcript : Aclaris Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M	05-07	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q4 Revenue $17.6M	02-27	MT
North American Morning Briefing : Stock Futures -2-	02-21	DJ
North American Morning Briefing : Stock Futures -2-	01-23	DJ
North American Morning Briefing : Stock Futures -2-	01-12	DJ
Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis	01-10	CI
Sun Pharmaceutical Signs Licensing Pact with Aclaris Therapeutics	12-05	MT
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia	12-05	CI
Aclaris Therapeutics to stop development of rheumatoid arthritis drug	11-13	RE
Aclaris Therapeutics, Inc. Announces Top-Line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update	11-13	CI
Aclaris Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q3 Revenue $9.3M	11-06	MT
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)	23-10-03	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q2 Revenue $1.9M	23-08-07	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Aclaris Therapeutics Q1 Loss Widens, Revenue Increases; Shares Down Pre-Bell	23-05-08	MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q1 Revenue $2.5M, vs. Street Est of $1.8M	23-05-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ACLS THER Nasdaq

Equities

Highlights

Filters